ArticleDiscover oncology2025
Anti-Müllerian hormone plays a bidirectional role in cancer: a multi-database and multi-method study.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- PIMO: pathway-based interpretable multiomics interactions for multiomics integration.Bioinformatics (Oxford, England) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAnti-Müllerian hormone (AMH) has been variably associated with cancer risk. This study integrated a meta-analysis, Mendelian randomization (MR), and transcriptomic analyses to clarify the relationship between AMH levels and various cancers.
methodsWe systematically reviewed observational studies from three major databases up to 2024 and selected 10 independent SNPs (r² < 0.001, P < 1 × 10⁻⁶) from GWAS meta-analyses (n = 7049) as instrumental variables. Cancer outcome data were obtained from the FinnGen database and additional GWAS datasets, while transcriptomic data from TCGA and GEO were analyzed across 33 tumor types.
resultsThe meta-analysis showed no overall significant association between circulating AMH and cancer risk (MD: -0.12; 95% CI: -0.38, 0.14). However, subgroup analysis showed that AMH concentration in the control group was different from patients with breast cancer and haematological malignancies. MR analysis revealed that increased AMH levels were causally linked to reduced risks of bladder cancer, melanoma, multiple myeloma, and thyroid cancer. Additionally, transcriptomic findings highlighted a significant association between AMH expression and patient prognosis, with AMH expression correlating with diverse immune cell infiltration patterns and signaling pathways.
conclusionsOur findings indicate a potential involvement of AMH in the development of cancer, suggesting the need for further clinical research to explore the possibility of targeting AMH for cancer prevention and diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.